Cargando…

Pharmacist-led iodinated contrast media infusion risk assessment service

Background: With the increasing development of medical imaging, the use of iodinated contrast media has become more widespread. Adverse reactions caused by iodinated contrast media have drawn much attention. Despite this, there is still a lack of unified standards for the safe infusion process of io...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Huiyan, Li, Yuan, Wu, Xiaoyan, Yu, Hongming, Zhang, Xin, Ge, Weihong, Yan, Simin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203501/
https://www.ncbi.nlm.nih.gov/pubmed/37229268
http://dx.doi.org/10.3389/fphar.2023.1161621
_version_ 1785045647385165824
author Jiang, Huiyan
Li, Yuan
Wu, Xiaoyan
Yu, Hongming
Zhang, Xin
Ge, Weihong
Yan, Simin
author_facet Jiang, Huiyan
Li, Yuan
Wu, Xiaoyan
Yu, Hongming
Zhang, Xin
Ge, Weihong
Yan, Simin
author_sort Jiang, Huiyan
collection PubMed
description Background: With the increasing development of medical imaging, the use of iodinated contrast media has become more widespread. Adverse reactions caused by iodinated contrast media have drawn much attention. Despite this, there is still a lack of unified standards for the safe infusion process of iodinated contrast media in clinical practice both domestically and internationally. Objectives: Establishing a risk management service system to better predict the risks associated with iodinated contrast media infusion, reduce the incidence of adverse reactions and minimize patient harm. Method: A prospective interventional study was carried out from April 2021 to December 2021 at Nanjing Drum Tower Hospital in China. During this study, a service system was established to manage the risks associated with the infusion of iodinated contrast media. Personalized risk identification and assessment were performed by a pharmacist-led multidisciplinary team before iodinated contrast media infusion. Early warning, prevention, and adverse reaction management were performed according to different risk levels during and after infusion. Results: A multidisciplinary team led by pharmacists was established to evaluate the risks associated with infusion of iodinated contrast media. A total of 157 patients with risk factors related to the iodinated contrast media were screened out, which prevented 22 serious adverse events and enhanced the quality of medical care. All participants expressed high satisfaction with the service. Conclusion: Through practical exploration, the pharmacist-led multidisciplinary team can provide advance warning and effectively limit the risks of adverse reactions caused by iodinated contrast media to a preventable and controllable level. This approach serves as a valuable reference for developing strategies and schemes to reduce the incidence of such reactions. Therefore, we encourage the implementation of this intervention in other areas of China.
format Online
Article
Text
id pubmed-10203501
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102035012023-05-24 Pharmacist-led iodinated contrast media infusion risk assessment service Jiang, Huiyan Li, Yuan Wu, Xiaoyan Yu, Hongming Zhang, Xin Ge, Weihong Yan, Simin Front Pharmacol Pharmacology Background: With the increasing development of medical imaging, the use of iodinated contrast media has become more widespread. Adverse reactions caused by iodinated contrast media have drawn much attention. Despite this, there is still a lack of unified standards for the safe infusion process of iodinated contrast media in clinical practice both domestically and internationally. Objectives: Establishing a risk management service system to better predict the risks associated with iodinated contrast media infusion, reduce the incidence of adverse reactions and minimize patient harm. Method: A prospective interventional study was carried out from April 2021 to December 2021 at Nanjing Drum Tower Hospital in China. During this study, a service system was established to manage the risks associated with the infusion of iodinated contrast media. Personalized risk identification and assessment were performed by a pharmacist-led multidisciplinary team before iodinated contrast media infusion. Early warning, prevention, and adverse reaction management were performed according to different risk levels during and after infusion. Results: A multidisciplinary team led by pharmacists was established to evaluate the risks associated with infusion of iodinated contrast media. A total of 157 patients with risk factors related to the iodinated contrast media were screened out, which prevented 22 serious adverse events and enhanced the quality of medical care. All participants expressed high satisfaction with the service. Conclusion: Through practical exploration, the pharmacist-led multidisciplinary team can provide advance warning and effectively limit the risks of adverse reactions caused by iodinated contrast media to a preventable and controllable level. This approach serves as a valuable reference for developing strategies and schemes to reduce the incidence of such reactions. Therefore, we encourage the implementation of this intervention in other areas of China. Frontiers Media S.A. 2023-05-09 /pmc/articles/PMC10203501/ /pubmed/37229268 http://dx.doi.org/10.3389/fphar.2023.1161621 Text en Copyright © 2023 Jiang, Li, Wu, Yu, Zhang, Ge and Yan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Jiang, Huiyan
Li, Yuan
Wu, Xiaoyan
Yu, Hongming
Zhang, Xin
Ge, Weihong
Yan, Simin
Pharmacist-led iodinated contrast media infusion risk assessment service
title Pharmacist-led iodinated contrast media infusion risk assessment service
title_full Pharmacist-led iodinated contrast media infusion risk assessment service
title_fullStr Pharmacist-led iodinated contrast media infusion risk assessment service
title_full_unstemmed Pharmacist-led iodinated contrast media infusion risk assessment service
title_short Pharmacist-led iodinated contrast media infusion risk assessment service
title_sort pharmacist-led iodinated contrast media infusion risk assessment service
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203501/
https://www.ncbi.nlm.nih.gov/pubmed/37229268
http://dx.doi.org/10.3389/fphar.2023.1161621
work_keys_str_mv AT jianghuiyan pharmacistlediodinatedcontrastmediainfusionriskassessmentservice
AT liyuan pharmacistlediodinatedcontrastmediainfusionriskassessmentservice
AT wuxiaoyan pharmacistlediodinatedcontrastmediainfusionriskassessmentservice
AT yuhongming pharmacistlediodinatedcontrastmediainfusionriskassessmentservice
AT zhangxin pharmacistlediodinatedcontrastmediainfusionriskassessmentservice
AT geweihong pharmacistlediodinatedcontrastmediainfusionriskassessmentservice
AT yansimin pharmacistlediodinatedcontrastmediainfusionriskassessmentservice